6 Top Gainers In Healthcare Sector (BPTH, OHRP, PRTO...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Bio-Path Holdings Inc. (BPTH)

Gained 160.46% to close Wednesday's (Mar.6) trading at $12.02.

News: The clinical update to the previously reported interim analysis from Stage 1 of the Company's phase II trial of Prexigebersen for the treatment of acute myeloid leukemia reveals an improvement in efficacy profile and strong evidence of safety profile.

The Stage 1 of the phase II study evaluated the efficacy and safety of Prexigebersen in conjunction with low dose cytarabine (LDAC), a therapeutic regimen well-established in the treatment of acute myeloid leukemia patients who cannot or elect not to be treated with more intensive chemotherapy.

2. OHR Pharmaceutical Inc. (OHRP)

Gained 44.19% to close Wednesday's trading at $12.02.

News: No news

Recent events:

-- On February 21, 2019, the Company announced it has regained compliance with the minimum bid price requirement under NASDAQ "Bid Price Rule. -- A 1-for-20 reverse stock split was effected on February 4, 2019. -- On January 3, 2019, Ohr announced a definitive merger agreement with NeuBase Therapeutics Inc.

3. Tenax Therapeutics Inc. (TENX)

Gained 29.37% to close Wednesday's trading at $1.63.

News: No news

Clinical Trial:

A phase II trial of Levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), dubbed H-E-L-P Trial, is underway.

4. Aytu BioScience Inc. (AYTU)

Gained 29.09% to close Wednesday's trading at $1.42.

News: The Company has entered into a licensing agreement with SUDA Pharmaceuticals Ltd (ASX:SUD) to distribute ZolpiMist outside the United States and Canada.

ZolpiMist, an FDA-approved, prescription sleep aid indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation, was licensed by Aytu from Magna Pharmaceuticals, Inc. last July.

Under the licensing agreement signed today, SUDA will pay Aytu a portion of each upfront and milestone payment received from sublicensees, and Aytu will receive ongoing royalty payments on sales generated by SUDA's sublicensees as ZolpiMist is launched in their territories.

5. Proteon Therapeutics Inc. (PRTO)

Proteon is a late-stage biopharmaceutical company developing therapies to address some of the most urgent needs of hemodialysis and peripheral artery disease patients.

Gained 21.48% to close Wednesday's trading at $3.62.

News: No news

Near-term Catalyst:

Top-line data from the PATENCY-2 clinical trial are expected in March 2019.

PATENCY-2 is a phase III study of its lead drug candidate Vonapanitase in patients with chronic kidney disease undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis.

6. Diffusion Pharmaceuticals Inc. (DFFN)

Gained 18.16% to close Wednesday's trading at $4.49.

News: No news

Clinical Trials:

The Company's lead drug candidate is Trans Sodium Crocinate.

A phase III study of Trans Sodium Crocinate to target inoperable glioblastoma multiforme brain cancer, dubbed INTACT, is underway. The Company was given FDA clearance last September to conduct a phase II on-ambulance trial of Trans Sodium Crocinate for the treatment of stroke.